B7-1 (CD80) FC FUSION BIOTIN-LABELED

Biochem/physiol Actions

CD80is an efficient costimulatory molecule essential for immune surveillance during carcinogenesis. It inhibits cancer progression. It regulates the T cell activation to control immune response. Cell stress increases the CD80expression. Reduced expression of CD80is observed in colon carcinoma. High levels of CD80stimulate anti-tumor immune responses. Therefore, enhancing CD80 expression in tumors might serve as a potent approach for cancer immunotherapy. Urinary CD80 is recognized as an important biomarker for idiopathic nephrotic syndrome (INS). CD80might be involved in proteinuria, actin reorganization, and podocyte migration. Its expression in podocytes is associated with minimal change disease (MCD).

General description

Human secreted B7-1-Fc fusion protein, also known as CD80, with C-terminal Avitag^™ . GenBank Accession No. NM_005191, a.a 35-242 expressed in a HEK293 cell expression system and enzymatically biotin-labeled using Avitag^™ technology. MW = 52.5 kDa (monomer). This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

CD80 orB7-1 is expressed in the antigen-presenting cells (APC). The CD80 gene is mapped to human chromosome 3q13.33.

Legal Information

AviTag is a trademark of Avidity, LLC

Physical form

Aqueous solution